🇺🇸 FDA
Company

Autolus

Autolus Therapeutics plc

AUTL biotech USA

Quick answer

Autolus is a biotech company (AUTL) headquartered in LONDON, X0, USA with 11 tracked pipeline programs.

Pipeline (11)

project

AUTO CAR T cell therapy

Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy

Phase 2 · mab · active

1 trials project

AUTO1

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

Phase 2 · mab · active

2 trials project

AUTO2

Multiple Myeloma

Phase 2 · mab · terminated

1 trials project

AUTO3

Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2 · mab · terminated

1 trials project

AUTO3 (CD19/22 CAR T cells

B Acute Lymphoblastic Leukemia

Phase 2 · mab · completed

1 trials project

AUTO4

T Cell Non-Hodgkin Lymphoma

Phase 2 · mab · terminated

1 trials project

Obecabtagene Autoleucel

Acute Lymphoblastic Leukemia

Phase 2 · small_molecule · active

1 trials project

Obecabtagene autoleucel

Acute Lymphocytic Leukemia (ALL)

Phase 2 · small_molecule · active

1 trials project

Obecabtagene autoleucel

Lupus Nephritis

Phase 2 · mab · active

1 trials project

Obecabtagene autoleucel (obe-cel)

Progressive Multiple Sclerosis

Phase 1 · mab · active

1 trials project

Obecabtagene autoleucel (obe-cel)

Systemic Lupus Erythematosus

Phase 1 · mab · active

1 trials

Patents (8)

patent

US 12398194

Cell lexpressing two chimeric antigen receptors (CARs) at the cell surface

Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12325733

Binding domain

Expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12304942

Cell comprising a chimeric antigen receptor or a transgenic T-cell receptor and

Expires Mon May 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12269860

Compositions and methods comprising engineered chimeric antigen receptor and mod

Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12241068

CD79-specific chimeric antigen receptor

Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12234295

Chimeric transmembrane protein comprising antibody dimerization domains and a ty

Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12187769

Cell

Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12049510

Chimeric antigen receptor

Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)